The lower risk for diabetes associated with continued denosumab use in older adults added new evidence to consider when choosing an osteoporosis treatment option.
Assessment of overall anticholinergic burden is essential for patients taking multiple medicines
Polypharmacy is prevalent among older adults aged ≥65 years and often leads to unintended clinical consequences. Drugs with anticholinergic activity are frequently prescribed to older adults for a range of conditions, such as respiratory, cardiovascular, gastrointestinal, and genitourinary diseases, and mental disorders. However, anticholinergic activity is often considered an unwanted side effect, causing adverse events such as urinary retention, mouth dryness, constipation, cognitive decline, and falls.123
Previous epidemiological studies indicate that about 20-50% of older adults regularly receive drugs with anticholinergic effects, and one third to one half of the drugs commonly prescribed to older adults exhibit potential anticholinergic activity.34 Therefore, recognising the anticholinergic burden and its potential negative impacts on older people is important clinically. The link
MONDAY, Feb. 14, 2022 (HealthDay News) For patients with atrial fibrillation (AF) and diabetes mellitus (DM), non-vitamin K antagonist oral anticoagulants (NOACs) are associated with lower risks for diabetes